Delcath Systems (DCTH) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Delcath Systems (DCTH) PT Raised to $20 at BTIG
August 6, 2024 4:57 AM EDTBTIG analyst Marie Thibault raised the price target on Delcath Systems (NASDAQ: DCTH) to $20.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "The U.S. commercial launch is ramping quicker than we initially expected with Delcath Systems reporting total Q2 sales of $7.8M, including $6.6M from Hepzato and $1.2M from OUS Chemosat sales. This was well above consensus of $5.2M. Seven treating centers were active in the quarter, performing what we estimate were 36 combined... More



